Table 1.
Patient data before and after Glargine therapy
| Age (years) | Lumacaftor Ivacaftor | BMI z-score |
FEV1 (%) | Annual number of pulmonary exacerbations | Annual number of pulmonary exacerbations treated by intravenous antibiotics | |
|---|---|---|---|---|---|---|
| 2016 (before Glargine therapy) | 13.1 | NO | −1.58 | 90.4% | 7 | 4 |
| 2017 (1 year of Glargine therapy) | 14.5 | NO | −1.54 | 91% | 4 | 2 |
| 2018 (2 years of Glargine therapy) | 15.7 | YES | −1.47 | 75% | 2 | 0 |
| 2019 (3 years of Glargine therapy) | 16.3 | YES | −1.78 | 74% | 3 | 0 |
| 2020 (COVID-19 pandemic lockdown) | 17.0 | YES | −2.47 | 68% | 4 | 0 |
| 2020 (November) | 17.6 | YES | −1.58 | 71% | 4 | 0 |